SCHEMBL9890747

SCHEMBL9890747

NC(=O)Cc1ccccc1-c1cc(C(F)(F)F)ccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP3A4 P08684 1/20 0.44
KCNJ5 P48544 1/20 0.44
KCNJ3 P48549 1/20 0.44
CSNK1D P48730 1/20 0.42
TP53 P04637 1/20 0.41
GRIN2B Q13224 1/20 0.41
IL2 P60568 2/20 0.41
TACR1 P25103 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
RORC P51449 1/20 0.40
RORB Q92753 1/20 0.40
CYP2C9 P11712 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GPBAR1 Q8TDU6 1/20 0.40
TRPV1 Q8NER1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2394221 0.89 NPSR1 (0.44) ALDH1A1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL2395095 0.85 PTGDR2 (0.40) KCNJ5KCNJ3FFAR4ICMTPTGDR2
SCHEMBL9892668 0.82 POLQ (0.45) ALDH1A1CYP2C9ICMTPTGDR2
SCHEMBL9890740 0.82 PTGDR2 (0.46) TACR1ICMTPTGDR2
SCHEMBL2394997 0.82 DPP4 (0.40) ALDH1A1CYP2C19CYP3A4ICMT
SCHEMBL2393195 0.81 CXCL8 (0.43) ALDH1A1CYP2C19MEN1KMT2ATP53
SCHEMBL30591389 0.81 ALDH1A1 (0.48) ALDH1A1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL2394862 0.79 DPP4 (0.58) ALDH1A1CYP2C19KMT2ASMN1; SMN2
SCHEMBL9892688 0.79 PTGDR2 (0.53) ALDH1A1TACR1ICMTPTGDR2
SCHEMBL9890734 0.79 FFAR1 (0.49) CYP2C19KCNJ5KCNJ3TACR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885CYP1A2 72/4885CYP2C19 240/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885CYP1A2 72/4885CYP2C19 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.